Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 15, 2025Blood AdvancesOpen Access

Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

XDXavier Deschênes‐SimardMBMaria BrombergSDSean M. Devlin

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows varying efficacy of CD19-targeted CAR T-cell therapies in large B-cell lymphoma patients, suggesting product selection impacts survival outcomes.

Key Points

  • Tisa-cel was associated with significantly inferior progression-free survival compared to axi-cel, indicating potential treatment limitations.
  • Estimated 2-year overall survival rates were highest for axi-cel at 63%, while tisa-cel only achieved 45%, emphasizing product differences.
  • This retrospective multicenter cohort study evaluated clinical outcomes using a large sample size of 624 patients receiving CAR T-cell therapies.
  • Higher rates of cytokine release syndrome were observed with axi-cel, highlighting differing safety profiles across therapies.

Cite This Study

Deschênes‐Simard et al. (2025) studied this question.

synapsesocial.com/papers/68af2b68cf1dd9ea359e4e34https://doi.org/10.1182/bloodadvances.2025016778
View Full Paper
Ask AI
Bookmark
Share